AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01366144
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT01366144
Drug: Veliparib
RxNorm normalized name: veliparib
DrugBank: Veliparib (DB07232)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00472550
Drug: esomeprazole 20 mg
RxNorm normalized name: esomeprazole 20 MG
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00299182
Drug: AMG 531
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm A: AMG531 - 1, 3, or 10 mcg/kg subcutaneous injection administered on on days -5 and 5 (pre and post chemotherapy dose) beginning with Cycle 2; OR, Arm A: AMG531 - 1, 3, or 10 mcg/kg subcutaneous injection administered on on days 5 and 7 (post chemotherapy doses only) beginning with Cycle 2.
Trial: NCT02477566
Drug: Long-acting Triptorelin
DrugBank: Triptorelin (DB06825)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pituitary down-regulation with Long-acting Triptorelin 1.875mg during the luteal phase
Trial: NCT02477566
Drug: Short-acting Triptorelin
RxNorm normalized name: Short-acting sulfonamides
DrugBank: Triptorelin (DB06825)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pituitary down-regulation with Short-acting Triptorelin 0.1mg/d,x10d, then 0.05mg/d until E2\<40pg/ml in serum, was initiated during the luteal phase
Trial: NCT00299182
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 375 mg/m\^2 by vein over 4-6 hour infusion day 1, each cycle.
Trial: NCT04138849
Drug: BBT-877 single dose
RxNorm normalized name: BBT-877
DrugBank: BBT-877 (DB18668)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsule, single dose.
Trial: NCT00299182
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.4 mg/m\^2/dose (maximum 2 mg) by vein over 15 minutes Days 5 and 12, Cycles 1,3,\& 5.
Trial: NCT00299182
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 40 mg/day by mouth or by vein days 2-5 and 12-15, Cycles 1,3,\& 5.
Trial: NCT00299182
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 g/m\^2 by vein over 2 hours every 12 hours for 4 doses, days 3 \& 4; OR,1 g/m\^2 by vein over 2 hours every 12 hours for 4 doses, days 3 \& 4 for patients \> 60 years and for patients with serum creatinine \> 1.5 mg/dL; Cycles 2,4,\& 6.
Trial: NCT01841177
Drug: Milrinone
RxNorm normalized name: Milrinone
DrugBank: Milrinone (DB00235)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Milrinone is a potent selective phosphodiesterase (PDE) type III inhibitor which stimulates myocardial function (inotropy), causes peripheral vasodilatation (afterload reduction) and improves myocardial relaxation (lusitropy).
Trial: NCT02422524
Drug: PA-824
RxNorm normalized name: PAS
DrugBank: Aminosalicylic acid (DB00233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pretomanid (PA-824) is a nitroimidazooxazine. All subjects will receive a single oral dose of 200 mg Pretomanid on day 1.
Trial: NCT04167358
Drug: Linerixibat
RxNorm normalized name: LINERIXIBAT
DrugBank: Linerixibat (DB11729)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants will receive linerixibat.
Trial: NCT03719768
Drug: Avelumab
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will be given 800 mg Avelumab as a one hour intravenous infusion once every 2 weeks.
Trial: NCT03047213
Drug: Sapanisertib
RxNorm normalized name: SAPANISERTIB
DrugBank: Sapanisertib (DB11836)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00001258
Drug: Oxygen-15 Water
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03467191
Drug: Alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: target BAC .08%
Trial: NCT04225117
Drug: enfortumab vedotin
RxNorm normalized name: ENFORTUMAB VEDOTIN
DrugBank: Enfortumab vedotin (DB13007)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intravenous (IV) infusion
Trial: NCT04225117
Drug: pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV infusion
Trial: NCT03738852
Drug: Insulin
RxNorm normalized name: Insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: standard insulin regimen
Trial: NCT00318552
Drug: Meropenem
RxNorm normalized name: Meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01849146
Drug: Adavosertib
RxNorm normalized name: Adavosertib
DrugBank: Adavosertib (DB11740)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01849146
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT04477343
Drug: SX-682
RxNorm normalized name: SX-682
DrugBank: SX-682 (DB19210)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allosteric inhibitor to human CXCR1 and CXCR2 receptor
Trial: NCT04477343
Drug: Nivolumab Injectable Product
RxNorm normalized name: nivolumab Injectable Product
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: humanized monoclonal antibody to program cell death receptor 1 (PD1)
Trial: NCT04252365
Drug: Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given i.v.
Trial: NCT04252365
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given i.v.
Trial: NCT03714308
Drug: Ivt. Aflibercept (Eylea, BAY86-5321)
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Treatment is applied according to routine clinical practice and independent of the study setting.
Trial: NCT02008721
Drug: EGCG as putative neuroprotective agent
RxNorm normalized name: EGCG
DrugBank: Epigallocatechin gallate (DB12116)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with 800 mg - 1200 mg EGCG as putative neuroprotective agent
Trial: NCT01593527
Drug: Triamcinelone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinelone acetonide 40 mg i.m.
Trial: NCT00112489
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00112489
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01466803
Drug: Vorikonazole
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The subject will be given vorikonazole twice a day for 5 days prior to the study. The dose will be 400 mg twice a day on day one ans 200 mg twice a day on days 2-5.
Trial: NCT00394446
Drug: MPC-6827
RxNorm normalized name: GIVI-MPC
DrugBank: GIVI-MPC (DB17905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-hour intravenous infusion given once weekly for 3 consecutive weeks on a 28 day cycle
Trial: NCT01254071
Drug: Dutasteride (0.5mg); Tamsulosin hydrochloride (0.2mg); fixed dose combination product of duatsteride (0.5mg) and tamsulosin hydrochloride (0.2mg)
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In the first dosing session, twenty-two subjects of each cohort will receive the FDC capsule (dutasteride and tamsulosin hydrochloride (0.5mg/0.2mg) and the other 22 will receive commercial capsules of dutasteride 0.5mg and commercial tablets of tamsulosin hydrochloride 0.2mg co-administered. Following a wash-out period of at least 28 days, those subjects who received the FDC capsule in session 1, will be co-administered commercial capsules of dutasteride 0.5mg and commercial tablets of tamsulosin hydrochloride 0.2mg while those who were co-administered commercial capsules of dutasteride 0.5mg and commercial tablets of tamsulosin hydrochloride 0.2mg in session 1 will receive the FDC capsule in the second dosing session.
Trial: NCT02058472
Drug: G3041
RxNorm normalized name: Galsulfase
DrugBank: Galsulfase (DB01279)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01205828
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Temozolomide 150 mg/m2/day PO Days 1-5 every 28 days
Trial: NCT01205828
Drug: ABT-888
RxNorm normalized name: ABT-925
DrugBank: ABT-288 (DB15192)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-888 40 mg BID PO Days 1-7 every 28 days
Trial: NCT03341286
Drug: TK3
RxNorm normalized name: Trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tryptophan and thiamine as on oral supplement
Trial: NCT00449410
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00449410
Drug: ezetimibe
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02952729
Drug: XMT-1522
RxNorm normalized name: XMT-2056
DrugBank: XMT-2056 (DB18230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one intravenous dose administered in-clinic every 21 days
Trial: NCT00656773
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.15 mg/kg, IV following by 0.075 mg/kg every 3 minutes during 15 minutes
Trial: NCT02867904
Drug: Methylprednisolone (40 mg depomedrol, 1ml, injection)
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Experimental Drug
Trial: NCT04562610
Drug: All oral administration group
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects in the oral administration group will receive the following pre-emptive analgesic drugs, acetaminophen 1,000mg, Celecoxib 200mg and gabapentin 600mg via the oral route prior to operation. In addition they will receive the antifibrinolytic drug, tranexamic acid 2,000mg via an oral route as well prior to operation.
Trial: NCT00194909
Drug: sildenafil (Viagra)
RxNorm normalized name: sildenafil Oral Tablet [Viagra]
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02867904
Drug: Marcaine (4ml 0.5%, injection)
RxNorm normalized name: bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control
Trial: NCT01003886
Drug: Doxazosin mesylate GITS
RxNorm normalized name: Doxazosin Mesylate
DrugBank: Doxazosin (DB00590)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxazosin mesylate GITS 4mg to 8mg once daily
Trial: NCT00199485
Drug: Angelica Sinensis
RxNorm normalized name: ANGELICA SINENSIS ROOT
DrugBank: Angelica sinensis root (DB14336)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angelica Sinensis / placebo
Trial: NCT00096668
Drug: TOCOSOL(R) Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01518283
Drug: Cabazitaxel 10 mg/m2
DrugBank: Cabazitaxel (DB06772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cabazitaxel 10 mg/m2 in a 1-hour infusion on days 1, 8, 15 and 22 of 5-week cycles.
Trial: NCT00786812
Drug: Nilotinib
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01491295
Drug: Tenofovir disoproxil fumarate
RxNorm normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tenofovir disoproxil fumarate 300mg QD for 36 months (adjust dosage according to renal function)
Trial: NCT01528813
Drug: Amorolfine lacquer
RxNorm normalized name: amorolfine
DrugBank: Amorolfine (DB09056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To each compromised ungual unit randomly assigned to this group, it will be applied amorolfine lacquer weekly for a period of 06 months.
Trial: NCT01458366
Drug: Bendamustine
RxNorm normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Phase 1: Given via IV at the following dose levels:~* Level 1: 70 mg/m2~* Level -1: 50 mg/m2~* Level 2: 90 mg/m2~* Level 3: 120 mg/m2~Phase II: Given via IV on Days 1 and 2 of each cycle at the maximum-tolerated dose level found in the Phase I portion of the study.
Trial: NCT01458366
Drug: Ofatumumab
RxNorm normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Phase II~* Cycle 1: 300 mg via IV on Day 1 and 1000 mg via IV on Day 3~* Cycles 2 and 3: 1000 mg via IV on Day 1
Trial: NCT01458366
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Phase II: AUC 5 via IV on Day 2 of each cycle
Trial: NCT01458366
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Phase II: 100 mg/m2 via IV on Days 1, 2, and 3 of each cycle
Trial: NCT04189094
Drug: Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoposide and cisplatin (carboplatin) plus Sintilimab induction therapy will be administered for 2 cycles and then thoracic radiotherapy (45 Gy/30 fractions) be administered with concurrent EP/EC chemotherapy for 2cycles. Patients who achieve CR or PR then receive prophylactic cranial irradiation (PCI, 25 Gy/10 fractions).Sintilimab maintenance therapy will be administered once every 3 week for 13 cycles.
Trial: NCT04189094
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide will be administered IV 100mg/m2 on days 1-3, 22-24, 43-45 and 64-66.
Trial: NCT04189094
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cisplatin will be administered IV 80mg/m2 on days 1, 22, 43 and 64.
Trial: NCT00593138
Drug: dex-methylphenidate
DrugBank: Dexmethylphenidate (DB06701)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The drug is administered as a capsule by mouth. Participants are assigned to receive either 20, 30 or 40 mg doses before each scan visit.
Trial: NCT02039479
Drug: Lithium Carbonate
RxNorm normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lithium as Add on to every necessary treatment as usual
Trial: NCT00597233
Drug: insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00195598
Drug: VENLAFAXINE
RxNorm normalized name: Venlafaxine
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00195598
Drug: Paroxetine
RxNorm normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01338636
Drug: Ambrisentan
RxNorm normalized name: Ambrisentan
DrugBank: Ambrisentan (DB06403)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 5 mg orally every day for 4 weeks. At Week 4, if ambrisentan 5 mg was tolerated, the dose was increased to 10 mg every day for the remainder of the 24-week period.
Trial: NCT04091867
Drug: sEphB4-HSA with chemotherapy
RxNorm normalized name: SEphB4-HSA
DrugBank: SEphB4-HSA (DB14797)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sEphB4-HSA is a fusion protein combining the soluble extracellular EphB4 domain with albumin that targets the ephrin B2 receptor, which is thought to mediate resistance to EGFR-targeted therapy, and acts as a radiosensitizer by enhancing DNA damage and promoting apoptosis. Concurrent chemotherapy drug (either cisplatin or carboplatin): Per treating physician discretion, and treatment plan is based per NCCN guidelines. These can be administered in tri-weekly or weekly doses during the radiation period. The participant will receive the first infusion on Day 15 (+/- 3 days).
Trial: NCT04091867
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Loading dose 400 mg/m2 on D9 Concurrent dose 250mg/m2 weekly D15± 3 day window
Trial: NCT03845179
Drug: DPP-4 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of DPP-4 inhibitor in active treatment period
Trial: NCT02229266
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 cycle of consolidation chemotherapy with high-dose cytarabine
Trial: NCT00451932
Drug: FK778
RxNorm normalized name: Teriflunomide
DrugBank: Teriflunomide (DB08880)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00163111
Drug: Conventional amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00211484
Drug: Anecortave Acetate
RxNorm normalized name: Anecortave acetate
DrugBank: Anecortave acetate (DB05288)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00776724
Drug: Taxotere , Epirubicin
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Taxotere 70 mg/m2 1hr iv infusion / Epirubicin 90 mg/m2 (TE) iv infusion on day 1.
Trial: NCT00507091
Drug: ZD6474 (vandetanib) 100mg
RxNorm normalized name: vandetanib 100 MG
DrugBank: Vandetanib (DB05294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: once daily oral tablet
Trial: NCT00507091
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intravenous infusion
Trial: NCT00507091
Drug: 5-Fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intravenous infusion
Trial: NCT00507091
Drug: ZD6474 (vandetanib) 300mg
RxNorm normalized name: vandetanib 300 MG
DrugBank: Vandetanib (DB05294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: once daily oral tablet
Trial: NCT00842582
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azacitidine 20 milligrams per meter squared subcutaneous once daily for 7 days.
Trial: NCT00842582
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azacitidine 40 milligrams per meter squared subcutaneous once daily for 7 days.
Trial: NCT00842582
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azacitidine 75 milligrams per meter squared subcutaneous once daily for 7 days.
Trial: NCT00644189
Drug: Clofarabine
RxNorm normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Taken orally once a day (in the AM) on days 1 through 21 of a 28-day cycle for a maximum of 6 cycles.
Trial: NCT02728622
Drug: Tamoxifen
RxNorm normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: endocrine treatment
Trial: NCT02020577
Drug: Cetuximab( erbitux®)
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: once per week
Trial: NCT02020577
Drug: Afatinib
RxNorm normalized name: Afatinib
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: once per day
Trial: NCT00912860
Drug: Interferon beta-1a
RxNorm normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: serum free Avonex given IM once a week
Trial: NCT03294161
Drug: Immucillin DI4G
RxNorm normalized name: Immucillin A
DrugBank: Galidesivir (DB11676)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immucillin DI4G was administered by topical use at 2% concentration once a day for 20 days associated with Meglumine antimoniate administered by intravenous route at a dosage of 20mg/kg/day, during 20 days.
Trial: NCT00484094
Drug: sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dosage and treatment duration will be decided by physician's discretion considering patient's clinical situations
Trial: NCT02000934
Drug: TAK-659
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-659 tablet
Trial: NCT04250922
Drug: TMZ
RxNorm normalized name: TMZ
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: TMZ will be administered at 75 mg/m2, orally, once daily, continuously from Day 1 of radiotherapy to the last day of radiation for a maximum of 49 days.~During the Maintenance (Adjuvant) Phase, all subjects will receive oral TMZ 150 - 200 mg/m2 once daily on Days 1 - 5 of each 28-day cycle for 6 cycles.
Trial: NCT03294161
Drug: Meglumine antimoniate
RxNorm normalized name: meglumine antimoniate
DrugBank: Meglumine antimoniate (DB13732)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for topical use once a day at the ulcer for 20 days associated with Meglumine antimoniate administered as the standard treatment for cutaneous leishmaniasis by intravenous route at a dosage of 20mg/kg/day, during 20 days.
Trial: NCT04155983
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The drug will be administered in the same dosage in both arms. The location of the injection will vary by arm.
Trial: NCT04390139
Drug: XCEL-UMC-BETA
RxNorm normalized name: XCEL-UMC-BETA
DrugBank: Human Umbilical Cord Mesenchymal Stem Cells (DB15726)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration on top of the standard administered treatment